Bernstein Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)
Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb yesterday. The company’s shares closed yesterday at $56.48.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and Pfizer. According to TipRanks, Breen has an average return of 20.4% and an 86.27% success rate on recommended stocks.
In addition to Bernstein, Bristol-Myers Squibb also received a Hold from Scotiabank’s Louise Chen in a report issued on June 1. However, on June 5, Guggenheim maintained a Buy rating on Bristol-Myers Squibb (NYSE: BMY).
Based on Bristol-Myers Squibb’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $11.49 billion and a net profit of $2.68 billion. In comparison, last year the company earned a revenue of $11.2 billion and had a net profit of $2.46 billion
Read More on BMY:
Disclaimer & DisclosureReport an Issue
- Acting FDA head vows to block political interference, Endpoint News says
- Bristol-Myers Squibb: Emerging Oncology Portfolio Supports Durable Growth; Buy Rating Reiterated with Unchanged $70 Price Target
- Arcus enters clinical trial collaboration, supply agreement with Bristol Myers
- Bristol-Myers Squibb’s Italian Anticoagulant Study: Real-World Signals for BMY Investors
- FDA issues draft guidance to help accelerated cell, gene therapies for patients
